The Rockville biotech says two versions of its ADHD drug could serve a potential $7 billion market.
SUBSCRIBE
Biohealth Innovation
Founding Member of
Biohealth Innovation
The Rockville biotech says two versions of its ADHD drug could serve a potential $7 billion market.